High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors
Open Access
- 12 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (16) , 5043-5049
- https://doi.org/10.1158/1078-0432.ccr-07-4551
Abstract
Purpose: Peptide receptors are frequently overexpressed in human tumors, allowing receptor-targeted scintigraphic imaging and therapy with radiolabeled peptide analogues. Neuropeptide Y (NPY) receptors are new candidates for these applications, based on their high expression in specific cancers. Because NPY receptors are expressed in selected sarcoma cell lines and because novel treatment options are needed for sarcomas, this study assessed the NPY receptor in primary human sarcomas.Keywords
This publication has 32 references indexed in Scilit:
- NPY receptors in human cancer: A review of current knowledgePeptides, 2007
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 2006
- Neuropeptide Y receptors in renal cell carcinomas and nephroblastomasInternational Journal of Cancer, 2005
- Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/neu in synovial sarcomaCancer, 2005
- From Transcription Profile to Expression: The Signaling Repertoire of the SK-N-MC Neuroepithelioma Cell-LineJournal of Receptors and Signal Transduction, 2004
- c-kit Expression in Pediatric Solid TumorsThe American Journal of Surgical Pathology, 2002
- Novel Peptide Conjugates for Tumor-Specific ChemotherapyJournal of Medicinal Chemistry, 2001
- Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106–01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cellsJournal of Bone and Mineral Research, 1992
- Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell linesZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Parathyroid hormone and noradrenaline‐induced enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line (UMR 106) is inhibited by neuropeptide YActa Physiologica Scandinavica, 1988